J P M O R G A N Asia Pacific Equity Research 14 July 2026 Eisai (4523) FDA approves Leqembi IQLIK for initiation dosing Eisai and Biogen announced on July 14 that the FDA has approved Leqembi IQLIK (lecanemab-irmb subcutaneous autoinjector) as an initiation dose for the treatment of early Alzheimer's disease. This subcutaneous (SC) administration option is an alternative to intravenous (IV) administration, with two 250mg injections (500mg in total) administered once weekly approved as the initiation regimen ...